Comprehensive Cancer Care Services

DR. J. THADDEUS BECK CO-AUTHORS STUDY OF GROUNDBREAKING BREAST CANCER TREATMENT:

Press Release

  FOR INFORMATION CONTACT:

Derek Champagne

479.422.7427

Derek@TheArtistEvolution.com

For Immediate Release

LOCAL DOCTOR CO-AUTHORS STUDY OF GROUNDBREAKING BREAST CANCER TREATMENT:

Fayetteville, Ark. – December 20, 2011

A local doctor co-authored the study of a breakthrough treatment for postmenopausal women with advanced forms of breast cancer. On average, the new treatment extended the life of the patients in the clinical trial by nearly seven months.

As part of Highlands Oncology Group’s role in a series of world-wide clinical trials, Dr. J. Thaddeus Beck participated in the study with doctors from around the globe, including some from the University of Texas MD Anderson Cancer Center.

“It is a privilege to provide access to the newest therapies for patients in our community,” Beck said. “I am so proud of the patients that volunteer their time to help create new knowledge and advance the care for all breast cancer patients around the world.”

Beck attended the recent San Antonio Breast Cancer Symposium where the results of the study were presented to a global audience. The annual Symposium draws breast cancer experts from more than 90 countries, according to the event’s website.

The New England Journal of Medicine, which has been in print since 1812, also published the study on Dec. 7.

Highlands Oncology Group is just one of 189 centers in 24 countries that participated in clinical trials of this new treatment, according to NEJM’s publication of the study.

The clinical trials focused on the effectiveness and safety of combining a drug called Everolimus with another treatment called Exemestane in treating postmenopausal women with advanced breast cancer. The study found that for women with hormone-receptor positive breast cancer, combining the two treatments slows the development of cancer, on average increasing life expectancy by 6.9 months, according to the study.

This study is just one of the many clinical trials Highlands Oncology Group has participated in over the last 14 years as part of the their ongoing battle against cancer.

The study was supported by Swiss pharmaceutical company Novartis.

To read the complete study, please visit: http://www.nejm.org/doi/full/10.1056/NEJMoa1109653. To learn more about Highlands Oncology Group, please visit: http://www.highlandsoncologygroup.com/.

# # #

Highlands Oncology Group is a state-of-the-art cancer treatment facility in Northwest Arkansas with a world-class team of specialists that is committed to providing the highest quality healthcare and to enhancing the quality of life of their patients and their loved ones in a friendly, comfortable environment. Highlands offers the latest technologies in diagnostic imaging and radiation therapies, as well as onsite labs, a pharmacy, and an infusion center. They also offer access to clinical trials, multidisciplinary clinics, and support groups. Highlands Oncology Group is helping patients win the battle against cancer every day.

Bookmark the permalink.